Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cash Flows Related Disclosures [Abstract]
Net loss	$ 324,022us-gaap_NetIncomeLoss	$ (1,315,318)us-gaap_NetIncomeLoss	$ (4,705,227)us-gaap_NetIncomeLoss	$ (6,833,659)us-gaap_NetIncomeLoss
Gain on revaluation of derivative warrants	(2,850,171)	(1,597,372)	(3,368,977)	(2,263,756)
Scenario, Previously Reported [Member]
Cash Flows Related Disclosures [Abstract]
Net loss	(505,716)		(5,534,965)
Gain on revaluation of derivative warrants	(2,020,433)		(2,539,239)
Restatement Adjustment [Member]
Cash Flows Related Disclosures [Abstract]
Net loss	829,738		829,738
Gain on revaluation of derivative warrants	$ (829,738)		$ (829,738)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.